Endo International PLC (NASDAQ:ENDP)‘s stock had its “hold” rating reaffirmed by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Sunday.

Other equities research analysts have also issued research reports about the company. Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target for the company in a research note on Wednesday, May 17th. William Blair reaffirmed a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Canaccord Genuity set a $14.00 price target on Endo International PLC and gave the stock a “hold” rating in a research note on Monday, May 22nd. Zacks Investment Research lowered Endo International PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Mizuho reaffirmed a “buy” rating and set a $19.00 price target (up previously from $18.00) on shares of Endo International PLC in a research note on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $17.33.

Endo International PLC (ENDP) traded down 7.310% during trading on Friday, hitting $11.475. The stock had a trading volume of 3,984,161 shares. The company has a 50-day moving average of $11.73 and a 200-day moving average of $12.05. Endo International PLC has a 52 week low of $9.70 and a 52 week high of $24.93. The stock’s market capitalization is $2.56 billion.

Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company earned $1.08 earnings per share. On average, equities analysts expect that Endo International PLC will post $3.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Endo International PLC (ENDP) Given Hold Rating at Oppenheimer Holdings, Inc.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/24/endo-international-plc-endp-given-hold-rating-at-oppenheimer-holdings-inc.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in ENDP. Norges Bank acquired a new position in shares of Endo International PLC during the fourth quarter worth about $26,929,000. Macquarie Group Ltd. increased its position in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares in the last quarter. Americafirst Capital Management LLC acquired a new position in shares of Endo International PLC during the first quarter worth about $286,000. Hartford Investment Management Co. acquired a new position in shares of Endo International PLC during the first quarter worth about $1,363,000. Finally, Nationwide Fund Advisors increased its position in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares in the last quarter. Institutional investors own 93.15% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.